Influence of diabetes on left ventricular systolic and diastolic function and on long-term outcome after cardiac resynchronization therapy

Diabetes Care

Volumn 36, Issue 4, 2013, Pages 985-991

  Höke, Ulas ^a,b   Thijssen, Joep ^a   Van Bommel, Rutger J ^a   Van Erven, Lieselot ^a   Van Der Velde, Enno T ^a   Holman, Eduard R ^a   Schalij, Martin J ^a   Bax, Jeroen J ^a   Delgado, Victoria ^a   Marsan, Nina Ajmone ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b ROYAL NETHERLANDS ACADEMY OF ARTS AND SCIENCES   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE DERIVATIVE; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN; SPIRONOLACTONE; SULFONYLUREA;

AGED; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; DIABETIC PATIENT; DIASTOLIC DYSFUNCTION; ELECTROCARDIOGRAM; FEMALE; HEART DEATH; HEART FAILURE; HEART LEFT VENTRICLE CONTRACTION; HEART LEFT VENTRICLE FILLING; HEART LEFT VENTRICLE FUNCTION; HUMAN; ISCHEMIC CARDIOMYOPATHY; KIDNEY FUNCTION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PROGNOSIS; REGISTER; SYSTOLIC DYSFUNCTION;

AGED; CARDIAC RESYNCHRONIZATION THERAPY; DIABETES COMPLICATIONS; DIASTOLE; FEMALE; HUMANS; MALE; MIDDLE AGED; SYSTOLE; VENTRICULAR REMODELING;

EID: 84875418506     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc12-1116     Document Type: Article

References (38)

1. Roger VL, Go AS, Lloyd-Jones DM, et al.; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statisticsd2011 update: a report from the American Heart Association. Circulation 2011;123:e18-e209
2. Wild S, Roglic G, Green A, Sicree R, King H. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27:1047-105
3. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974;34:29-34
4. Soläng L, Malmberg K, Rydén L. Diabetes mellitus and congestive heart failure. Further knowledge needed. Eur Heart J 1999;20:789-795
5. Nichols GA, Hillier TA, Erbey JR, Brown JB. Congestive heart failure in type 2 diabetes: prevalence, incidence, and risk factors. Diabetes Care 2001;24:1614-161
6. He J, Ogden LG, Bazzano LA, Vupputuri S, Loria C, Whelton PK. Risk factors for congestive heart failure in US men and women: NHANES I epidemiologic followup study. Arch Intern Med 2001;161: 996-1002
7. Shehadeh A, Regan TJ. Cardiac consequences of diabetes mellitus. Clin Cardiol 1995;18:301-305
8. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol 2006;47:693-700
9. Ashrafian H, Frenneaux MP, Opie LH. Metabolic mechanisms in heart failure. Circulation 2007;116:434-448
10. From AM, Scott CG, Chen HH. The development of heart failure in patients with diabetes mellitus and pre-clinical diastolic dysfunction a population-based study. J Am Coll Cardiol 2010;55:300-305
11. van Heerebeek L, Hamdani N, Handoko ML, et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 2008; 117:43-51
12. Soliman OI, van Dalen BM, Theuns DA, et al. The ischemic etiology of heart failure in diabetics limits reverse left ventricular remodeling after cardiac resynchronization therapy. J Diabetes Complications 2009;23:365-370
13. Hoppe UC, Freemantle N, Cleland JG, Marijianowski M, Erdmann E. Effect of cardiac resynchronization on morbidity and mortality of diabetic patients with severe heart failure. Diabetes Care 2007; 30:722-724
14. Martin DT, McNitt S, Nesto RW, Rutter MK, Moss AJ. Cardiac resynchronization therapy reduces the risk of cardiac events in patients with diabetes enrolled in the multicenter automatic defibrillator implantation trial with cardiac resynchronization therapy (MADIT-CRT). Circ Heart Fail 2011;4:332-338
15. Fantoni C, Regoli F, Ghanem A, et al. Longterm outcome in diabetic heart failure patients treated with cardiac resynchronization therapy. Eur J Heart Fail 2008; 10:298-307
16. Mangiavacchi M, Gasparini M, Genovese S, et al. Insulin-treated type 2 diabetes is associated with a decreased survival in heart failure patients after cardiac resynchronization therapy. Pacing Clin Electrophysiol 2008;31:1425-1432
17. van Bommel RJ, Borleffs CJ, Ypenburg C, et al. Morbidity and mortality in heart failure patients treated with cardiac resynchronization therapy: influence of preimplantation characteristics on long-term outcome. Eur Heart J 2010;31:2783-279
18. Dickstein K, Vardas PE, Auricchio A, et al.; ESC Committee for Practice Guidelines (CPG). 2010 focused update of ESC guidelines on device therapy in heart failure: an update of the 2008 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure and the 2007 ESC guidelines for cardiac and resynchronization therapy. Developed with the special contribution of the Heart Failure Association and the European Heart Rhythm Association. Eur Heart J 2010;31:2677-268
19. Albertsen AE, Nielsen JC, Pedersen AK, Hansen PS, Jensen HK, Mortensen PT. Left ventricular lead performance in cardiac resynchronization therapy: impact of lead localization and complications. Pacing Clin Electrophysiol 2005;28:483-488
20. World Health Organization. Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications.Geneva, WorldHealth Org., 1999
21. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1997;20(Suppl. 1): 1183-1197
22. Rector TS, Kubo SH, Cohn JN. Validity of the Minnesota Living with Heart Failure questionnaire as a measure of therapeutic response to enalapril or placebo. Am J Cardiol 1993;71:1106-1107
23. Guyatt GH, Sullivan MJ, Thompson PJ, et al. The 6-minute walk: a newmeasure of exercise capacity in patients with chronic heart failure. Can Med Assoc J 1985;132: 919-923
24. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976;16:31-41
25. Lang RM, Bierig M, Devereux RB, et al.; Chamber Quantification Writing Group; American Society of Echocardiography's Guidelines and Standards Committee; European Association of Echocardiography. Recommendations for chamber quantification: a report from the American Society of Echocardiography's Guidelines and Standards Committee and the Chamber Quantification Writing Group, developed in conjunction with the European Association of Echocardiography, a branch of the European Society of Cardiology. J Am Soc Echocardiogr 2005;18: 1440-1463
26. Bleeker GB, Bax JJ, Fung JW, et al. Clinical versus echocardiographic parameters to assess response to cardiac resynchronization therapy. Am J Cardiol 2006;97:260-263
27. ZoghbiWA, Enriquez-Sarano M, Foster E, et al.; American Society of Echocardiography. Recommendations for evaluation of the severity of native valvular regurgitation with two-dimensional and Doppler echocardiography. J Am Soc Echocardiogr 2003;16:777-802
28. Bax JJ, Bleeker GB, Marwick TH, et al. Left ventricular dyssynchrony predicts response and prognosis after cardiac resynchronization therapy. J Am Coll Cardiol 2004;44: 1834-1840
29. Nagueh SF, Appleton CP, Gillebert TC, et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009;10:165-193
30. Paulus WJ, Tschöpe C, Sanderson JE, et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 2007;28:2539-2550
31. Cleland JG, Daubert JC, Erdmann E, et al.; Cardiac Resynchronization- Heart Failure (CARE-HF) Study Investigators. The effect of cardiac resynchronization on morbidity and mortality in heart failure. N Engl J Med 2005;352:1539-1549
32. St John Sutton MG, Plappert T, Abraham WT, et al.; Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Study Group. Effect of cardiac resynchronization therapy on left ventricular size and function in chronic heart failure. Circulation 2003;107:1985-1990
33. Galderisi M. Diastolic dysfunction and diabetic cardiomyopathy: evaluation by Doppler echocardiography. J Am Coll Cardiol 2006;48:1548-1551
34. Rodrigues B, Cam MC, McNeill JH. Myocardial substrate metabolism: implications for diabetic cardiomyopathy. J Mol Cell Cardiol 1995;27:169-179
35. Shanks M, Antoni ML, Hoke U, et al. The effect of cardiac resynchronization therapy on left ventricular diastolic function assessed with speckle-tracking echocardiography. Eur J Heart Fail 2011;13: 1133-1139
36. Ghali JK, Boehmer J, Feldman AM, et al. Influence of diabetes on cardiac resynchronization therapy with or without defibrillator in patients with advanced heart failure. J Card Fail 2007;13:769-773
37. Bai R, Di Biase L, Elayi C, et al.Mortality of heart failure patients after cardiac resynchronization therapy: identification of predictors. J Cardiovasc Electrophysiol 2008;19:1259-1265
38. Shah RV, Altman RK, Park MY, et al. Usefulness of hemoglobin a(1c) to predict outcome after cardiac resynchronization therapy in patients with diabetes mellitus and heart failure. Am J Cardiol 2012;110:683-688